MEMatthew J. Everly

Matthew J. Everly

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Matthew J. Everly has a total of 106 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Response to: The expanded role of the transplant pharmacist: A 10-year follow-up by Lichvar et al

    by Angela Q. Maldonado, Bharath Ravichandran, Timothy Horwedel, Kimi Ueda, Christin Rogers Marks, Matthew Everly, Erika Aldag, James Fleming

  • Antibiotic pretreatment alleviates liver transplant damage in mice and humans

    by Kojiro Nakamura, Shoichi Kageyama, Takahiro Ito, Hirofumi Hirao, Kentaro Kadono, Antony Aziz, Kenneth J. Dery, Matthew J. Everly, Kojiro Taura, Shinji Uemoto, et al.

    Although modifications of gut microbiota with antibiotics (Abx) influence mouse skin and cardiac allografts, its role in orthotopic liver transplantation (OLT) remains unknown. We aimed to determine whether and how recipient Abx pretreatment may affect hepatic ischemia-reperfusion injury (IRI) and OLT outcomes. Mice (C57BL/6) with or without Abx treatment (10 days) were transplanted with allogeneic (BALB/c) cold-stored (18 hours) livers, followed by liver and blood sampling (6 hours). We divided 264 human OLT recipients on the basis of duration of pre-OLT Abx treatment into control (Abx-free/Abx n = 108) and Abx treatment (Abx ≥10days; n = 156) groups; OLT biopsy (Bx) samples were collected 2 hours after OLT (n = 52). Abx in mice mitigated IRI-stressed OLT (IRI-OLT), decreased CCAAT/enhancer-binding protein homologous protein (CHOP) (endoplasmic reticulum [ER] stress), enhanced LC3B (autophagy), and inhibited inflammation, whereas it increased serum prostaglandin E2 (PGE2) and hepatic PGE2 receptor 4 (EP4) expression. PGE2 increased EP4, suppressed CHOP, and induced autophagosome formation in hepatocyte cultures in an EP4-dependent manner. An EP4 antagonist restored CHOP, suppressed LC3B, and recreated IRI-OLT. Remarkably, human recipients of Abx treatment plus OLT (Abx-OLT), despite severe pretransplantation clinical acuity, had higher EP4 and LC3B levels but lower CHOP levels, which coincided with improved hepatocellular function (serum aspartate aminotransferase/serum aspartate aminotransferase [sALT/sAST]) and a decreased incidence of early allograft dysfunction (EAD). Multivariate analysis identified “Abx-free/Abx <10 days” as a predictive factor of EAD. This study documents the benefits of Abx pretreatment in liver transplant recipients, identifies ER stress and autophagy regulation by the PGE2/EP4 axis as a homeostatic underpinning, and points to the microbiome as a therapeutic target in OLT.


  • Prevalence and Impact of De Novo Donor‐Specific Antibodies During a Multicenter Immunosuppression Withdrawal Trial in Adult Liver Transplant Recipients

    by Vadim Jucaud, Abraham Shaked, Michele DesMarais, Peter Sayre, Sandy Feng, Josh Levitsky, Matthew J. Everly

    The development of human leukocyte antigen (HLA) donor‐specific antibody/antibodies (DSA) is not well described in liver transplant (LT) patients undergoing immunosuppression (IS) withdrawal protocols despite the allograft risk associated with de novo DSA (dnDSA). We analyzed the development of dnDSA in 69 LT patients who received calcineurin inhibitor monotherapy and were enrolled in the ITN030ST study. Of these 69 patients, 40 stable patients were randomized to IS maintenance (n = 9) or IS minimization (n = 31). Nine of the 31 IS minimization patients achieved complete withdrawal and were free of IS. Among patients who achieved stable IS monotherapy 1 year after transplantation, the prevalence of dnDSA was 18.8%. Acute rejections and the biopsy‐proven findings disqualifying patients from IS withdrawal attempt were factors associated with dnDSA development (P = 0.011 and P = 0.041, respectively). Among randomized patients, dnDSA prevalence was 51.7% after IS minimization and 66.7% in IS‐free patients. dnDSA prevalence in patients on IS maintenance was 44.4%. dnDSA development during IS minimization was a risk factor for acute rejection (P = 0.015). The majority of dnDSA were against HLA‐DQ antigens (78.7%). Conclusion. During the first year following transplantation, acute rejections increase the risk of developing dnDSA, so dnDSA positivity should be considered for IS withdrawal eligibility; during IS minimization, dnDSA development was associated with acute rejection, which prevented further IS withdrawal attempts.


  • Factors at de novo donor‐specific antibody initial detection associated with allograft loss: a multicenter study

    by Carrie A Schinstock, Darshana M Dadhania, Matthew J Everly, Byron Smith, Manish Gandhi, Evan Farkash, Vijay K Sharma, Milagros Samaniego-Picota, Mark D Stegall

    We aimed to evaluate patient factors including nonadherence and viral infection and de novo donor specific antibody (dnDSA) characteristics [Total IgG, C1q, IgG3, and IgG4] as predictors of renal allograft failure in a multicenter cohort with dnDSA. We performed a retrospective observational study of 113 kidney transplant recipients with dnDSA and stored sera for analysis. Predictors of death‐censored allograft loss were assessed by Cox‐proportional modeling Death censored allograft survival was 77.0%(87/113) during a median follow‐up of 2.2(IQR 1.2‐3.7) years after dnDSA detection. Predictors of allograft failure included: medication nonadherence [HR 6.5 (95% CI 2.6‐15.9)], prior viral infection requiring immunosuppression reduction [HR 5.3 (95% CI 2.1‐13.5)], IgG3 positivity [HR 3.8(95%CI 1.5, 9.3)], and time post‐transplant (years) until DSA detection [HR 1.2 (95% CI 1.0,1.3)]. In the 67 patients who were biopsied at dnDSA detection; chronic antibody mediated rejection [HR 11.4(95% CI 2.3, 56.0)] and mixed rejection [HR 7.4(95% CI 2.2, 24.8)] were associated with allograft failure. We conclude that patient factors, including a history of viral infection requiring immunosuppression reduction or medication nonadherence, combined with DSA and histologic parameters must be considered to understand the risk of allograft failure in patients with dnDSA.


  • Open Access

    The importance of drug safety and tolerability in the development of new immunosuppressive therapy for transplant recipients: The Transplant Therapeutics Consortium’s position statement

    by Mark D. Stegall, Kenneth Troy Somerville, Matthew J. Everly, Roslyn B. Mannon, A. Osama Gaber, M. Roy First, Neetu Agashivala, Vanessa Perez, Kenneth A. Newell, Randall E. Morris, et al.


  • Open Access

    Long-term outcomes of eculizumab-treated positive crossmatch recipients: Allograft survival, histologic findings, and natural history of the donor-specific antibodies

    by Carrie A. Schinstock, Andrew J. Bentall, Byron H. Smith, Lynn D. Cornell, Matthew Everly, Manish J. Gandhi, Mark D. Stegall


  • Racial differences in incident de novo donor-specific anti-HLA antibody among primary renal allograft recipients: results from a single center cohort study

    by Matthew J. Everly, Kimberly P. Briley, Carl E. Haisch, Georg Dieplinger, Paul Bolin, Scott A. Kendrick, Claire Morgan, Angela Q. Maldonado, Lorita M. Rebellato

    Controversy exists as to whether African American (AA) transplant recipients are at risk for developing de novo donor-specific anti-human leukocyte antigen (HLA) antibody (dnDSA). We studied 341 HLA-mismatched, primary renal allograft recipients who were consecutively transplanted between 3/1999 and 12/2010. Sera were collected sequentially pre- and post-transplant and tested for anti-HLA immunoglobulin G (IgG) via single antigen bead assay. Of the 341 transplant patients (225 AA and 116 non-AA), 107 developed dnDSA at a median of 9.2 months post-transplant. AA patients had a 5-year dnDSA incidence of 35%. This was significantly higher than the 5-year dnDSA incidence for non-AA patients (21%). DQ mismatch (risk) and receiving a living-related donor (LRD) transplant (protective) were transplant factors associated with dnDSA. Within the AA patient cohort, HLA-DQ mismatch, not-receiving a LRD transplant, non-adherence, and BK viremia were the most common factors associated with early dnDSA (occurring <24 months post-transplant). Non-adherence and pre-transplant diabetes history were the strong precursors to late dnDSA. Despite the higher rates of dnDSA in the AA cohort, post-dnDSA survival was the same in AA and non-AA patients. This study suggests that DQ matching, increasing LRD transplantation in AA patients, and minimizing under-immunosuppression will be key to preventing dnDSA.


  • Incidence and impact of anti‐HLA‐DP antibodies in renal transplantation

    by Mareike Hörmann, Georg Dieplinger, Lorita M. Rebellato, Kimberly P. Briley, Paul Bolin, Claire Morgan, Carl E. Haisch, Matthew J. Everly

    Background: The role of anti‐HLA‐DP antibodies in renal transplantation is poorly defined. This study describes the impact of donor (donor‐specific antibody [DSA]) and non‐donor‐specific antibodies against HLA‐DP antigens in renal transplant patients.Methods: Of 195 consecutive patients transplanted between September 2009 and December 2011, 166 primary kidney recipients and their donors were typed (high‐resolution) for DP antigens. Sera taken pre‐transplant and at 1, 3, 6, 9, and 12 months, and annually post‐transplant were retrospectively tested for anti‐DP antibodies using single‐antigen beads.Results: In 81 (49%) patients, anti‐DP antibodies were found; 64% (n=52) of patients were positive in the pre‐transplant samples and 36% (n=29) were positive exclusively post‐transplant. The median time from transplantation to antibody was 20.9 months. Fifty‐five percent (n=16) of the de novo anti‐DP antibodies were accompanied by another de novo DSA. Anti‐DP antibody‐positive patients had a higher rate of rejection (compared with anti‐DP antibody‐negative patients, P=.01). The estimated glomerular filtration rate declined more with anti‐DP antibodies (−5.5% vs +26%).Conclusions: Antibodies against HLA‐DP antigens are common. De novo anti‐DP antibodies commonly appear after acute rejection and accompany DSA, which makes it difficult to determine whether anti‐DP antibodies are the cause or the consequence of graft injury.


  • Onset and progression of de novo donor‐specific anti‐human leukocyte antigen antibodies after BK polyomavirus and preemptive immunosuppression reduction

    by G. Dieplinger, M.J. Everly, K.P. Briley, C.E. Haisch, P. Bolin, A.Q. Maldonado, W.T. Kendrick, S.A. Kendrick, C. Morgan, P.I. Terasaki, et al.

    Background: BK polyomavirus (BKPyV) viremia/nephropathy and reduction in immunosuppression following viremia may increase the risk of alloimmune activation and allograft rejection. This study investigates the impact of BKPyV viremia on de novo donor anti‐human leukocyte antigen (HLA)‐specific antibodies (dnDSA).Patients and methods: All primary renal transplants at East Carolina University from March 1999 to December 2010, with at least 1 post‐transplant BKPyV viral load testing, were analyzed. Patients were negative for anti‐HLA antibodies to donor antigens (tested via single antigen beads) at transplantation and at first BKPyV testing.Results: Nineteen of 174 patients (11%) tested positive for BKPyV viremia. Within 24 months of BKPyV viremia detection, 79% of BKPyV‐viremic patients developed dnDSA. Only 20% of BKPyV viremia‐persistent cases, compared to 86% of BKPyV viremia‐resolved cases, developed dnDSA (P = 0.03). Poor allograft survival was evident in BKPyV viremia‐persistent patients (60% failure by 2 years post BKPyV diagnosis) and in BKPyV viremia‐resolved patients with dnDSA (5‐year post BKPyV diagnosis allograft survival of 48%).Conclusions: Post‐transplant BKPyV viremia and preemptive immunosuppression reduction is associated with high rates of dnDSA. When preemptively treating BKPyV viremia, dnDSA should be monitored to prevent allograft consequences.